In 2024, the U.S. healthcare industry spent $6.1 billion on Pfizer’s COVID-19 therapy Paxlovid, a 6,922.8% increase from 2023 expenditure data, according to a recent study. The research, published ...

With the potential for pharmaceutical import tariffs spurring a rush of life sciences investments in the U.S., AbbVie is ...

Following a positive readout for its closely watched PD-1xVEGF bispecific ivonescimab, Akeso has won the FDA’s go-ahead for ...

AbbVie raised its 2025 profit forecast on Friday after strong sales of its newer immunology drugs Skyrizi and Rinvoq helped ...

The global neurology clinical trials market is poised for substantial growth over the next decade, with projections forecasting an increase in market size from USD 5.7 billion in 2022 to a remarkable ...

Fortrea Holdings Inc.’s FTRE share price has surged by 5.64%, which has investors questioning if this is right time to sell.

LEXINGTON, KENTUCKY / ACCESS Newswire / April 24, 2025 / Today, NX Development Corp ("NXDC"), a Lexington, KY based life sciences company, announced the return of the sales and marketing rights for ...